NEW YORK (AP) – There’s a chance you might get a treatment for syphilis, but not necessarily one that works.

Some scientists say it may take decades before one is available.

A new study published Monday in the journal Science Advances found that scientists have found a treatment that may help more than just the most aggressive cases.

“We are now seeing the potential of a treatment specifically targeting the very early stages of the disease,” said Thomas Wojtowicz, a virologist at the Johns Hopkins University School of Medicine and a co-author of the study.

“This is a significant advance in the field of early-stage syphilis.”

This drug may offer a new treatment that could be used at an earlier stage, in patients who are at higher risk of complications or who are currently in a state of chronic infection.

“The drug, called piperacillin, was developed by the University of Michigan and has already been approved by the Food and Drug Administration for treating about half of patients with a severe form of syphilis known as septicaemia.

It works in about 1 in 5 cases of syphilitic men who do not respond to other treatments.

Wojtowksi’s team is currently testing piperaca to see if it works in the most advanced stages of syringomyelia.

This is the most severe form, meaning it can cause infections in the lungs, skin and joints.

Wojtkiewicz says his team is studying how this drug might work in people who are more advanced in their disease.”

In patients who have more advanced disease, we have not been able to find any indication of efficacy in that state, so we are hopeful that we may be able to do some kind of early clinical trial,” he said.”

It’s a very exciting drug, and we hope to get it to clinical trials soon.

“Patients who are in a serious or stable condition may require surgery or a combination of antibiotics.

The drug was originally developed by researchers at the University Health Network in Cleveland, but it was approved in 2014 by the FDA.

Wozniak said the drug’s safety record is well-documented.

Wozniaks study was the first to analyze the effectiveness of the drug and look at whether it might work with patients who had not previously been treated.

The research team compared the drug to other existing treatments.

The drug has been approved for use in adults and children.”

Our primary goal was to identify and characterize the efficacy of the new drug and to test it for the early stages,” said Woznik, a senior author of the paper.”

There is still a lot of work to be done to get to the clinical trial stage.

This was a very early stage of the development and validation of this drug.